Is there a risk of platelet decline while taking Eltrombopag (Revlan)?

Eltrombopag (Eltrombopag) is an oral thrombopoietin receptor agonist (TPO-RA), mainly used to treat idiopathic thrombocytopenic purpura (ITP), chronic liver disease-related thrombocytopenia and preventive elevated platelets before surgery. Its mechanism of action is by activating the thrombopoietin receptor, promoting the differentiation and maturation of megakaryocytes in the bone marrow, thereby increasing the number of platelets. However, patients may still be at risk for platelet decline during use, especially if the drug is discontinued or the dose is not adjusted appropriately.

In clinical practice, eltrombopag can significantly increase platelet levels in most patients, but some patients may experience a rebound decline in platelets after stopping the drug or missing doses, and sometimes platelet levels are even lower than the pre-treatment baseline. This decrease is mainly related to the sudden drop in drug blood concentration, delayed recovery of bone marrow megakaryocyte production, and individual differences. Therefore, drug discontinuation and dose adjustment need to be carried out strictly in accordance with medical instructions.

In addition, the risk of thrombocytopenia may be affected by comorbidities or other medications. If the patient also has factors such as bone marrow suppression, infection, or chemotherapy, the ability to produce platelets may be further impaired, thereby increasing the risk of decline. To reduce the risk, doctors usually dynamically adjust the dose based on platelet counts, gradually reduce the dose rather than suddenly stopping the drug if necessary, and regularly monitor platelets and related laboratory indicators.

In general, although eltrombopag can effectively increase platelets, attention should be paid to the possibility of platelet decline. During use, patients should regularly review blood routine, take medication strictly as directed by the doctor, and avoid stopping medication or changing dosage on their own. At the same time, once platelet count decreases, abnormal bleeding or ecchymosis occurs, you should seek medical treatment promptly so that the medication plan can be adjusted and corresponding treatment measures taken to ensure medication safety and stable efficacy.

Reference materials:https://www.drugs.com/